Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EZN-2208

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CamptothecinPolyethylene Glycols
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
BACKGROUND EZN-2208 is a water-soluble PEGylated conjugate of the topoisomerase inhibitor SN38, the active metabolite of… Expand
  • table I
  • table II
  • table III
Is this relevant?
2013
2013
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
PurposeThis study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
BACKGROUND Irinotecan is cytotoxic in patients with advanced colorectal cancer (CRC). SN-38 (10-hydroxy-7-ethyl-camptothecin) is… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors
SummaryBackground Anti-angiogenic therapies such as bevacizumab upregulate hypoxia-inducible factor-1α (HIF-1α), a possible… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2012
2012
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
BACKGROUND EZN-2208 is a water-soluble, polyethylene glycol drug conjugate of SN38, which is the active moiety of irinotecan. In… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2012
2012
EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
BRCA1 dysfunction in hereditary breast cancer causes defective homology-directed DNA repair and sensitivity towards DNA damaging… Expand
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects
Topoisomerase I inhibitors down-regulate HIF-1α leading to tumor growth inhibition, but only while maintaining sustained levels… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor
Purpose: Treatment of neuroblastoma is successful in less than half of patients with high-risk disease. The antitumor activity of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2009
2009
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.
Examination of the clinical utility of SN38 (10-hydroxy-7-ethyl-camptothecin), the active metabolite of CPT-11, has not been… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model
Purpose: Clinical development of SN38, the active metabolite of camptothecin-11 (CPT-11), has been hampered due to its poor… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE